245 related articles for article (PubMed ID: 19199918)
21. Obesity management--new perspectives.
Jéquier E
Ther Umsch; 2000 Aug; 57(8):473-7. PubMed ID: 11026081
[TBL] [Abstract][Full Text] [Related]
22. Possible anti-obesity therapeutics from nature--a review.
Yun JW
Phytochemistry; 2010 Oct; 71(14-15):1625-41. PubMed ID: 20732701
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological therapies for obesity.
Kaplan LM
Gastroenterol Clin North Am; 2005 Mar; 34(1):91-104. PubMed ID: 15823441
[TBL] [Abstract][Full Text] [Related]
24. [Are drugs necessary in the treatment of obesity?].
Ivković-Lazar T; Stokić E; Lepsanović L
Med Pregl; 2002; 55(1-2):23-7. PubMed ID: 12037933
[TBL] [Abstract][Full Text] [Related]
25. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
Sabuncu T; Nazligul Y; Karaoglanoglu M; Ucar E; Kilic FB
Rom J Gastroenterol; 2003 Sep; 12(3):189-92. PubMed ID: 14502318
[TBL] [Abstract][Full Text] [Related]
26. Anti-obesity drugs: status quo and recent advances.
Zhu HJ; Jin ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Jun; 33(3):243-7. PubMed ID: 21718603
[TBL] [Abstract][Full Text] [Related]
27. Current pharmacotherapy for obesity.
Srivastava G; Apovian CM
Nat Rev Endocrinol; 2018 Jan; 14(1):12-24. PubMed ID: 29027993
[TBL] [Abstract][Full Text] [Related]
28. Pharmacotherapy for obesity.
Ioannides-Demos LL; Proietto J; McNeil JJ
Drugs; 2005; 65(10):1391-418. PubMed ID: 15977970
[TBL] [Abstract][Full Text] [Related]
29. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the Effects and Mechanism of L-Citrulline on Anti-obesity by Appetite Suppression in Obese/Diabetic KK-Ay Mice and High-Fat Diet Fed SD Rats.
Kudo M; Yoshitomi H; Momoo M; Suguro S; Yamagishi Y; Gao M
Biol Pharm Bull; 2017; 40(4):524-530. PubMed ID: 28381807
[TBL] [Abstract][Full Text] [Related]
31. Pharmacotherapy of obesity: an update.
Schurgin S; Siegel RD
Nutr Clin Care; 2003; 6(1):27-37. PubMed ID: 12841428
[TBL] [Abstract][Full Text] [Related]
32. [The "problem obesity": viewpoint of the internist].
Guagnano MT; Manigrasso MR; Capani F; Davì G
Ann Ital Chir; 2005; 76(5):407-11. PubMed ID: 16696212
[TBL] [Abstract][Full Text] [Related]
33. Appetite suppressants. A review.
Silverstone T
Drugs; 1992 Jun; 43(6):820-36. PubMed ID: 1379155
[TBL] [Abstract][Full Text] [Related]
34. Current pharmacological approaches to the treatment of obesity.
Hauner H
Int J Obes Relat Metab Disord; 2001 May; 25 Suppl 1():S102-6. PubMed ID: 11466601
[TBL] [Abstract][Full Text] [Related]
35. [The harmfulness of drugs and slimming substances--a toxicologist's point of view].
Kujawa A; Szponar J; Szponar E; Zapalska-Pozarowska K; Kostek H
Przegl Lek; 2012; 69(8):548-51. PubMed ID: 23243925
[TBL] [Abstract][Full Text] [Related]
36. [Drug treatment of obesity].
Svendsen OL; Toubro S; Breum L; Bruun JM; Astrup AV
Ugeskr Laeger; 2006 Jan; 168(2):163-7. PubMed ID: 16403342
[TBL] [Abstract][Full Text] [Related]
37. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
38. Long-term health benefits of appetite suppressants remain unproven.
Paumgartten FJ
Rev Saude Publica; 2011 Dec; 45(6):1192-6. PubMed ID: 22232806
[TBL] [Abstract][Full Text] [Related]
39. Central and peripheral molecular targets for antiobesity pharmacotherapy.
Valentino MA; Lin JE; Waldman SA
Clin Pharmacol Ther; 2010 Jun; 87(6):652-62. PubMed ID: 20445536
[TBL] [Abstract][Full Text] [Related]
40. Novel approaches to the pharmacotherapy of obesity.
Gouni-Berthold I; Brüning JC; Berthold HK
Curr Pharm Des; 2013; 19(27):4938-52. PubMed ID: 23278490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
